Does the media prefer JAZZ or AXSM?

In the previous week, Axsome Therapeutics had 8 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 10 mentions for Axsome Therapeutics and 2 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.84 beat Axsome Therapeutics' score of 1.17 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Axsome Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TAK or JAZZ?

Jazz Pharmaceuticals has a consensus target price of $272.89, suggesting a potential upside of 8.22%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Jazz Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media favor TAK or JAZZ?

In the previous week, Takeda Pharmaceutical had 2 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 4 mentions for Takeda Pharmaceutical and 2 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.84 beat Takeda Pharmaceutical's score of 0.16 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jazz Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer JAZZ or TEVA?

In the previous week, Teva Pharmaceutical Industries had 7 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 9 mentions for Teva Pharmaceutical Industries and 2 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.84 beat Teva Pharmaceutical Industries' score of 0.71 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Teva Pharmaceutical Industries 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to JAZZ or ONC?

In the previous week, BeOne Medicines had 7 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 9 mentions for BeOne Medicines and 2 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.84 beat BeOne Medicines' score of 0.43 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BeOne Medicines 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to JAZZ or RPRX?

In the previous week, Royalty Pharma had 5 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 7 mentions for Royalty Pharma and 2 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.84 beat Royalty Pharma's score of 0.98 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Royalty Pharma 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Jazz Pharmaceuticals (JAZZ) Competitors

$252.16 -0.91 (-0.36%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$250.42 -1.75 (-0.69%)

As of 07:20 AM Eastern

Compare

JAZZ vs. AXSM, TAK, TEVA, ONC, and RPRX

Should you buy Jazz Pharmaceuticals stock or one of its competitors? Jazz Pharmaceuticals's main competitors and comparable companies include Axsome Therapeutics (AXSM), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), and Royalty Pharma (RPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

In the previous week, Axsome Therapeutics had 8 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 10 mentions for Axsome Therapeutics and 2 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.84 beat Axsome Therapeutics' score of 1.17 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Axsome Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jazz Pharmaceuticals currently has a consensus price target of $272.89, suggesting a potential upside of 8.22%. Axsome Therapeutics has a consensus price target of $267.60, suggesting a potential upside of 22.64%. Given Axsome Therapeutics' higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.00
Axsome Therapeutics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Axsome Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.84	-$356.15M	$14.50	17.39
Axsome Therapeutics	$638.50M	17.90	-$183.17M	-$3.75	N/A

Jazz Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Axsome Therapeutics' net margin of -24.68%. Jazz Pharmaceuticals' return on equity of 33.97% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Axsome Therapeutics	-24.68%	-265.55%	-28.10%

Summary

Jazz Pharmaceuticals beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Takeda Pharmaceutical had 2 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 4 mentions for Takeda Pharmaceutical and 2 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.84 beat Takeda Pharmaceutical's score of 0.16 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jazz Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Jazz Pharmaceuticals has a consensus target price of $272.89, suggesting a potential upside of 8.22%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.00

Jazz Pharmaceuticals has lower revenue, but higher earnings than Takeda Pharmaceutical. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	2.08	-$1.01B	$0.34	54.01
Jazz Pharmaceuticals	$4.27B	3.84	-$356.15M	$14.50	17.39

Takeda Pharmaceutical has a beta of -0.08, meaning that its share price is 108% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Takeda Pharmaceutical's net margin of 3.80%. Jazz Pharmaceuticals' return on equity of 33.97% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Summary

Jazz Pharmaceuticals beats Takeda Pharmaceutical on 14 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Teva Pharmaceutical Industries?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

In the previous week, Teva Pharmaceutical Industries had 7 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 9 mentions for Teva Pharmaceutical Industries and 2 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.84 beat Teva Pharmaceutical Industries' score of 0.71 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Teva Pharmaceutical Industries	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jazz Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Jazz Pharmaceuticals' return on equity of 33.97% beat Teva Pharmaceutical Industries' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

Teva Pharmaceutical Industries has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.84	-$356.15M	$14.50	17.39
Teva Pharmaceutical Industries	$17.26B	2.53	$1.41B	$0.60	62.50

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Jazz Pharmaceuticals currently has a consensus target price of $272.89, suggesting a potential upside of 8.22%. Teva Pharmaceutical Industries has a consensus target price of $42.22, suggesting a potential upside of 12.60%. Given Teva Pharmaceutical Industries' higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.00
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Summary

Jazz Pharmaceuticals beats Teva Pharmaceutical Industries on 11 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to BeOne Medicines?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Jazz Pharmaceuticals currently has a consensus price target of $272.89, indicating a potential upside of 8.22%. BeOne Medicines has a consensus price target of $402.14, indicating a potential upside of 6.71%. Given Jazz Pharmaceuticals' higher probable upside, equities analysts clearly believe Jazz Pharmaceuticals is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.00
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

Jazz Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

BeOne Medicines has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.84	-$356.15M	$14.50	17.39
BeOne Medicines	$5.34B	7.74	$286.93M	$5.68	66.35

Jazz Pharmaceuticals has a net margin of 20.45% compared to BeOne Medicines' net margin of 10.70%. Jazz Pharmaceuticals' return on equity of 33.97% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
BeOne Medicines	10.70%	14.23%	7.82%

In the previous week, BeOne Medicines had 7 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 9 mentions for BeOne Medicines and 2 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.84 beat BeOne Medicines' score of 0.43 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
BeOne Medicines	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Jazz Pharmaceuticals and BeOne Medicines tied by winning 8 of the 16 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 18.8% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Jazz Pharmaceuticals currently has a consensus price target of $272.89, suggesting a potential upside of 8.22%. Royalty Pharma has a consensus price target of $60.86, suggesting a potential downside of 1.41%. Given Jazz Pharmaceuticals' higher probable upside, equities analysts plainly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	3.00
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Royalty Pharma has a net margin of 32.14% compared to Jazz Pharmaceuticals' net margin of 20.45%. Jazz Pharmaceuticals' return on equity of 33.97% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Royalty Pharma	32.14%	30.01%	14.91%

In the previous week, Royalty Pharma had 5 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 7 mentions for Royalty Pharma and 2 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 1.84 beat Royalty Pharma's score of 0.98 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Royalty Pharma	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Royalty Pharma has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.84	-$356.15M	$14.50	17.39
Royalty Pharma	$2.38B	14.93	$770.95M	$1.45	42.57

Jazz Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market.

Summary

Jazz Pharmaceuticals and Royalty Pharma tied by winning 8 of the 16 factors compared between the two stocks.

Get Jazz Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JAZZ vs. The Competition

Export

Metric	Jazz Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.43B	$12.20B	$7.16B	$12.86B
Dividend Yield	N/A	2.66%	2.55%	10.29%
P/E Ratio	17.39	779.77	268.96	24.23
Price / Sales	3.84	761.28	628.81	101.64
Price / Cash	15.56	96.52	78.23	52.73
Price / Book	3.41	12.06	13.22	6.25
Net Income	-$356.15M	$2.81B	$3.47B	$348.04M
7 Day Performance	2.57%	1.17%	2.29%	-0.17%
1 Month Performance	3.57%	2.61%	5.36%	2.66%
1 Year Performance	111.77%	8.75%	29.24%	21.01%

Jazz Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JAZZ Jazz Pharmaceuticals	4.1929 of 5 stars	$252.16 -0.4%	$272.89 +8.2%	+111.5%	$16.43B	$4.27B	17.39	2,890	Positive News
AXSM Axsome Therapeutics	3.4577 of 5 stars	$220.89 +3.8%	$265.55 +20.2%	+96.1%	$10.95B	$638.50M	N/A	380	Analyst Upgrade High Trading Volume
TAK Takeda Pharmaceutical	1.9993 of 5 stars	$17.55 +0.6%	N/A	+20.8%	$55.91B	$28.32B	51.62	47,000	Insider Trade
TEVA Teva Pharmaceutical Industries	3.5642 of 5 stars	$36.04 +1.9%	$42.00 +16.5%	+113.6%	$41.20B	$17.26B	60.07	33,950
ONC BeOne Medicines	3.9983 of 5 stars	$359.00 +3.1%	$402.14 +12.0%	+20.6%	$38.21B	$5.34B	63.20	12,000	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JAZZ) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, TAK, TEVA, ONC, and RPRX

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Jazz Pharmaceuticals compare to Takeda Pharmaceutical?

Summary

How does Jazz Pharmaceuticals compare to Teva Pharmaceutical Industries?

Summary

How does Jazz Pharmaceuticals compare to BeOne Medicines?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, TAK, TEVA, ONC, and RPRX

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Does the media prefer JAZZ or AXSM?

Do analysts recommend JAZZ or AXSM?

Do insiders & institutionals believe in JAZZ or AXSM?

Which has better earnings & valuation, JAZZ or AXSM?

Which has more volatility & risk, JAZZ or AXSM?

Is JAZZ or AXSM more profitable?

Summary

How does Jazz Pharmaceuticals compare to Takeda Pharmaceutical?

Do insiders and institutionals hold more shares of TAK or JAZZ?

Does the media favor TAK or JAZZ?

Do analysts prefer TAK or JAZZ?

Which has stronger valuation & earnings, TAK or JAZZ?

Which has more volatility and risk, TAK or JAZZ?

Is TAK or JAZZ more profitable?

Summary

How does Jazz Pharmaceuticals compare to Teva Pharmaceutical Industries?

Does the media prefer JAZZ or TEVA?

Which has more risk & volatility, JAZZ or TEVA?

Is JAZZ or TEVA more profitable?

Which has preferable valuation & earnings, JAZZ or TEVA?

Do insiders and institutionals believe in JAZZ or TEVA?

Do analysts recommend JAZZ or TEVA?

Summary

How does Jazz Pharmaceuticals compare to BeOne Medicines?

Do analysts recommend JAZZ or ONC?

Which has more risk and volatility, JAZZ or ONC?

Which has preferable earnings & valuation, JAZZ or ONC?

Is JAZZ or ONC more profitable?

Does the media refer more to JAZZ or ONC?

Do institutionals and insiders have more ownership in JAZZ or ONC?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Do insiders and institutionals have more ownership in JAZZ or RPRX?

Do analysts recommend JAZZ or RPRX?

Is JAZZ or RPRX more profitable?

Does the media refer more to JAZZ or RPRX?

Which has higher valuation & earnings, JAZZ or RPRX?

Which has more risk & volatility, JAZZ or RPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools